P2Y12 Inhibition in Patients Requiring OraláAnticoagulation After PercutaneousáCoronary Intervention: The SWAP-AC–2 Study
L Ortega-Paz, W Bor, F Franchi… - JACC: Cardiovascular …, 2024 - Elsevier
Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention: The SWAP-AC-2 Study
L Ortega-Paz, W Bor, F Franchi, WWA van den Broek… - 2024 - pubmed.ncbi.nlm.nih.gov
Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC–2 Study
L Ortega-Paz, W Bor, F Franchi, WWA van de Broek… - Cardiovascular … - jacc.org
Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC-2 Study.
L Ortega-Paz, W Bor, F Franchi… - JACC …, 2024 - europepmc.org
Background Among patients treated with a novel oral anticoagulant (NOAC) undergoing
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …
percutaneous coronary intervention (PCI), combination therapy with clopidogrel (ie, known …